[Adult acute lymphoblastic leukemia]

Area of Science:

• Hematology
• Oncology
• Immunogenetics

Context:

• Accurate diagnosis and classification of adult acute lymphoblastic leukemia (ALL) are crucial for effective treatment.
• WHO classification necessitates comprehensive clinical and biological evaluation.
• Specific subtypes like Burkitt ALL and Philadelphia chromosome-positive (Ph+) ALL require urgent and tailored interventions.

Purpose:

• To outline the diagnostic work-up and classification of adult ALL according to WHO guidelines.
• To highlight the urgent need for rapid diagnosis in specific ALL subtypes.
• To review current treatment strategies and their impact on survival rates for different ALL entities.

Summary:

• Diagnosis of adult ALL involves detailed clinical and biological assessment, including immunogenetics, for WHO classification.
• Burkitt ALL is an emergency with an 80% cure rate via chemotherapy and tumor lysis syndrome prevention.
• Philadelphia chromosome-positive (Ph+) ALL shows improved survival (70%) with combined chemotherapy and tyrosine-kinase inhibitors.
• For Philadelphia-negative ALL, minimal residual disease influences decisions on allogeneic stem cell transplantation versus chemotherapy, aiming for 60% cure rates.
• Outcomes for adult ALL patients over 60 remain challenging.

Impact:

• Improved diagnostic accuracy leads to better patient stratification and treatment selection for adult ALL.
• Targeted therapies and risk-factor identification are enhancing survival rates for specific ALL subtypes.
• The study underscores the need for continued research into optimizing treatments for elderly ALL patients.